Related Experiment Videos

Population pharmacokinetics of amphotericin B in children with malignant diseases

C E Nath1, A J McLachlan, P J Shaw

  • 1Department of Biochemistry, The Children's Hospital at Westmead, NSW, Australia. christan@chw.edu.au

British Journal of Clinical Pharmacology
|December 12, 2001
PubMed

Insights

A population pharmacokinetic model for amphotericin B (AmB) was developed in pediatric cancer patients. This model accurately predicts AmB concentrations, aiding in safe and effective dosing for children.

Area of Science:

  • Pharmacology
  • Pediatric Oncology
  • Clinical Pharmacy

Background:

  • Amphotericin B (AmB) is a critical antifungal agent used in pediatric patients with malignant diseases.
  • Optimizing AmB dosing is essential for efficacy and minimizing toxicity in this vulnerable population.
  • Existing pharmacokinetic data in children with cancer is limited.

Purpose of the Study:

  • To develop a robust population pharmacokinetic (PopPK) model for AmB in children undergoing cancer treatment.
  • To identify key covariates influencing AmB pharmacokinetics, such as weight and dose formulation.
  • To validate the predictive performance of the developed PopPK model.

Main Methods:

  • A two-compartment PopPK model was constructed using concentration-time data from 57 pediatric patients.
  • The P-Pharm software (version 1.5) was utilized for parameter estimation and covariate analysis.
  • Model performance was assessed using an independent validation group of 26 children.

Main Results:

  • Population pharmacokinetic parameters for clearance (CL) and volume of distribution (V) were estimated.
  • Significant covariate relationships were identified: CL was influenced by weight and dose formulation, while V was affected by weight.
  • The covariate model demonstrated unbiased and precise predictions in the validation cohort.

Conclusions:

  • A validated population pharmacokinetic model for AmB in pediatric cancer patients has been successfully developed.
  • This model provides a foundation for optimizing AmB dosing strategies in this population.
  • Future application of this model can inform the development of precise dosing guidelines for safe and effective AmB therapy.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...